Blog

“It’s a little bit morbid, but it’s to write what you want your obituary to say, and then try to live your life up to that,” Housel tells Fortune in discussing his latest book “The Art of Spending Money.” 

He isn’t the first to adopt the approach for living a fulfilled life. The sentiment echoes that of Berkshire Hathaway’s legendary investor, Warren Buffett, who says many of his life philosophies were gleaned from his right-hand man, Charlie Munger, who passed away in 2023.

“Early on, write your desired obituary, and then behave accordingly,” Buffett wrote in a previous shareholder letter in 2022. 

Now it’s one of Housel’s ways to measure legacy too: if it’s not important enough to take to the grave, it doesn’t matter at all. 

“If I were to write what I want my obituary to say, I would want it to hopefully say: ‘Morgan was a good husband, a good dad, a loving friend, helped his community, helped people in need’” he said.  

Housel’s new book breaks down spending as an art rather than a science 

Housel is known for his bestseller The Psychology of Money, which dissects how people’s previous beliefs, behaviors, and emotions impact finances. Now, he’s unveiling the psychology behind spending. 

Housel emphasizes that spending is not about getting things down to a science, it’s an art that shouldn’t have a “one size fits all” approach. How you’re spending it also makes all the difference: Housel says if a majority of your expenditures are material items, you haven’t yet learned the most important life lessons. 

Housel says that when he was in his 20s, his aspiration for the material world was at its highest– yearning for things like a new Ferrari or a mansion. Later in life, he realized that family and community took precedence over anything he had wanted to splurge on in his past. 

“When you do that exercise [writing your obituary], you immediately realize what you would not care about:  your salary, the size of your house, how often you bought a new car, where you went on vacation. That does not matter at all,” Housel added. 

Other successful founders have emphasized long-term legacy over short-term spending.

Jeff Bezos famously used a similar approach to decide to leave his cushy financial job and start Amazon, for instance.  

“I wanted to project myself forward to age 80 and say, ‘OK, now I’m looking back on my life. I want to have minimized the number of regrets I have,’” Bezos has previously explained. 

“50 or 60 years from now, I am not going to say, I wish I earned more and spent more. There’s a very good chance we’re going to look back and say, ‘I wish I was more helpful and more loving to the people who I really cared about in my life’,” Housel said. 

Fortune Global Forum returns Oct. 26–27, 2025 in Riyadh. CEOs and global leaders will gather for a dynamic, invitation-only event shaping the future of business. Apply for an invitation.

Earlybird registration is set to close at the end of October for C21’s new three-day format-focused market, conference and screenings event, which is set to take place in Lisbon between April 21 and 23, 2026.

The event is designed as a sales and acquisitions market, connecting buyers and sellers around formats, factual and drama. It will be supported by a two-track conference programme: the Future Formats Forum and The Content Acquisitions Summit.

Both these tracks will be focused on uncovering content trends, buyer priorities, and sales and coproduction opportunities across channels and platforms worldwide. They will mine data from C21’s ongoing Content Strategies premium report strand.

C21’s editor-in-chief & managing director David Jenkinson said: “The focus on formats and factual at Content Europe has been welcomed by the business and we are set to announce some significant speakers and initiatives around the event in the coming weeks. It’s clear the demand for a sales and acquisitions market in the spring is strong following the closure of MipTV, but what is also clear is that these genres are the ones currently defining global business.

“We have already taken additional space at The Marriott in Lisbon to accommodate high demand for the event and will be making a number of further announcements shortly.”

C21 has signed a deal with Amsterdam-based LineUp Industries to become an event partner on Content Europe, with founders Julian Curtis and Ed Louwerse joining the advisory board.

Curtis (left) said: “The demise of MipTV left a big gap in the formats calendar. Our sector will benefit hugely from a dedicated industry gathering and we’re looking forward to working with C21 in delivering an event that gives a voice to all parts of the business – indies to studios, big or small. We aim to make this not just a market but a fun celebration of what we do and the value we deliver.”

Content Europe has also announced that Formats Biz founder Chiara Duranti has joined the advisory board. “Chiara is a champion of global formats and her insights will provide a valuable contribution to the event,” Jenkinson added.

Duranti said: “I’m truly honoured to join the advisory board of Content Europe. As founder of FormatBiz, I believe it’s crucial to have a space that both tracks global trends in scripted and unscripted formats and supports real exchange between buyers and distributors. This new spring market is a timely and strategic response to the industry’s evolving needs.”

Further information will be announced shortly.

The building blocks of Content Europe are:

Subcutaneously administered systemic therapies are expected to reduce administration times, minimizing the time an individual treatment chair or room is needed while simultaneously giving patients the freedom to choose how to spend more of their time outside the clinic, according to J. Thaddeus Beck, MD, FACP.

The most recent regulatory approval of subcutaneous treatment was announced on September 19, 2025, when the FDA approved pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) for subcutaneous injection for use in adult and pediatric patients aged 12 years and older in all solid tumor indications approved for the intravenous (IV) formulation of pembrolizumab (Keytruda).^1,2

The agent was tested in the phase 3 Study MK-3475A-D77 (NCT05722015) in patients with untreated, metastatic non–small cell lung cancer (NSCLC) without EGFR, ALK, or ROS1 genomic tumor aberrations. Patients were randomly assigned to receive subcutaneous pembrolizumab (n = 251) or IV pembrolizumab administered every 6 weeks with platinum doublet chemotherapy.

The results showed that the predefined acceptance margin was met for the pharmacokinetic end points with the lower boundary, 96% CI for cycle 1 area under the curve 0 to 6 weeks, and 94% CI for cycle 3 C_trough, of the geometric mean ratios above the prespecified threshold of 0.8 for comparability. Descriptive analyses of efficacy also indicated that the confirmed objective response rate was 45% (95% CI, 39%-52%) in the subcutaneous arm vs 42% (95% CI, 33%-51%) in the IV arm. Progression-free survival and overall survival outcomes were also similar between arms.

“I think [this approval] is the wave of the future. [I expect that] more of these monoclonal [antibodies] will be given subcutaneously,” J. Thaddeus Beck, MD, FACP, medical oncologist at Highlands Oncology in Rogers, Arkansas, said in an interview with OncLive®.

In the interview, Beck discussed the regulatory agency’s approval of subcutaneous pembrolizumab, its significance for patients and providers, and considerations that should be made before the agent is introduced into clinical practices.

OncLive: What makes this approval of subcutaneous pembrolizumab meaningful?

Beck: The approval of the subcutaneous form of pembrolizumab gives us another option that we can use to tailor treatments for patients’ individual situations. The main benefit is the ease and simplicity of administration [since it allows for a] shortened administration time. It’s a 2.4 mL or 0.5 teaspoon size injection that can be given in seconds instead of [over 30 minutes].

We’ve had very good feedback from patients who are on the trial [about] how it really changed the way they thought about treatment. They liked the fact that it was shorter and quicker, so that they could be in and out. They could have more time to do what they wanted to do before and after their treatment, [providing] much more of a pleasant experience for them.

What will be the immediate effect of the approval?

The patients like it better. It will save chair time, so treatment chairs or rooms will not be occupied as long. You can cut the infusion time down. If it’s being given with another IV chemotherapy, you can drop the last infusion, given that it is subcutaneous, and the patients will have a better experience.

What is important to note about the design of the pivotal trial?

The trial was designed with two arms that compared sequential treatment. The first arm was IV therapy for [X] cycles, followed by subcutaneous therapy. The second arm was subcutaneous therapy, followed by IV therapy. Then patients were allowed to assess how they felt with the treatment and choose which one they’d like to continue with. Most patients chose the subcutaneous version.

There were no unique adverse effects or safety signals. Other than the administration difference, [the subcutaneous formulation] seemed to act in the same form and fashion [as the IV formulation].

What is your advice to those looking to integrate the subcutaneous formulation into their practice?

People have to get partially undressed [to receive the therapy], so you’ll need a private area to [allow for that]. We’re in the process of building a new facility, and we’re taking this change into account. We’re creating a whole separate fast track area where patients can [experience] the faster workflow and have more privacy, so they can take advantage of this program.